GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Equity-to-Asset

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Equity-to-Asset : -1.38 (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Paratek Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-201.4 Mil. Paratek Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was $145.8 Mil. Therefore, Paratek Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was -1.38.

The historical rank and industry rank for Paratek Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

PRTK' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.38   Med: 0.22   Max: 0.97
Current: -1.38

During the past 13 years, the highest Equity to Asset Ratio of Paratek Pharmaceuticals was 0.97. The lowest was -1.38. And the median was 0.22.

PRTK's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66 vs PRTK: -1.38

Paratek Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Paratek Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Equity-to-Asset Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 -0.16 -0.58 -0.70 -0.99

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -1.06 -0.99 -1.25 -1.38

Competitive Comparison of Paratek Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Paratek Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Equity-to-Asset falls into.



Paratek Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Paratek Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-171.042/172.538
=-0.99

Paratek Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=-201.365/145.792
=-1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paratek Pharmaceuticals  (NAS:PRTK) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Paratek Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Executives
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh director, officer: CEO 75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel officer: CLO, General Counsel & Sec. ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow officer: President & Chief Commercial C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner officer: Chief Development & Regulatory C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann director LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham director, officer: Exec. Chairman of the Board 890 WINTER STREET, WALTHAM MA 02451
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan officer: Chief Financial Officer 75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Headlines

From GuruFocus